These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

423 related articles for article (PubMed ID: 25689527)

  • 21. Ceftolozane/Tazobactam Plus Metronidazole for Complicated Intra-abdominal Infections in an Era of Multidrug Resistance: Results From a Randomized, Double-Blind, Phase 3 Trial (ASPECT-cIAI).
    Solomkin J; Hershberger E; Miller B; Popejoy M; Friedland I; Steenbergen J; Yoon M; Collins S; Yuan G; Barie PS; Eckmann C
    Clin Infect Dis; 2015 May; 60(10):1462-71. PubMed ID: 25670823
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ceftolozane/tazobactam dose regimens in severely/morbidly obese patients with complicated intra-abdominal infection or complicated urinary tract infection.
    Xiao AJ; Huntington JA; Long J; Caro L
    Int J Antimicrob Agents; 2018 Sep; 52(3):324-330. PubMed ID: 29596902
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Activity of ceftolozane/tazobactam against Pseudomonas aeruginosa and Enterobacterales isolates recovered from intensive care unit patients in Spain: The SUPERIOR multicentre study.
    García-Fernández S; García-Castillo M; Bou G; Calvo J; Cercenado E; Delgado M; Pitart C; Mulet X; Tormo N; Mendoza DL; Díaz-Regañón J; Cantón R;
    Int J Antimicrob Agents; 2019 May; 53(5):682-688. PubMed ID: 30769199
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Perspectives on the use of ceftolozane/tazobactam: a review of clinical trial data and real-world evidence.
    Martin-Loeches I; Bruno CJ; DeRyke CA
    Future Microbiol; 2024; 19(6):465-480. PubMed ID: 38252038
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ceftazidime-avibactam for the treatment of complicated urinary tract infections and complicated intra-abdominal infections.
    Mawal Y; Critchley IA; Riccobene TA; Talley AK
    Expert Rev Clin Pharmacol; 2015; 8(6):691-707. PubMed ID: 26420166
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised, pathogen-directed, phase 3 study.
    Carmeli Y; Armstrong J; Laud PJ; Newell P; Stone G; Wardman A; Gasink LB
    Lancet Infect Dis; 2016 Jun; 16(6):661-673. PubMed ID: 27107460
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Antimicrobial activity of ceftolozane/tazobactam against Enterobacteriaceae and Pseudomonas aeruginosa in the Czech Republic in 2016].
    Žemličková H; Jakubů V; Fridrichová M
    Klin Mikrobiol Infekc Lek; 2017 Dec; 23(4):132-135. PubMed ID: 29378381
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ceftolozane/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing urinary tract and intraabdominal infections in Europe: report from an antimicrobial surveillance programme (2012-15).
    Pfaller MA; Bassetti M; Duncan LR; Castanheira M
    J Antimicrob Chemother; 2017 May; 72(5):1386-1395. PubMed ID: 28165526
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In vitro activity of ceftolozane-tazobactam against Enterobacterales and Pseudomonas aeruginosa causing urinary, intra-abdominal and lower respiratory tract infections in intensive care units in Portugal: The STEP multicenter study.
    García-Fernández S; García-Castillo M; Melo-Cristino J; Pinto MF; Gonçalves E; Alves V; Vieira AR; Ramalheira E; Sancho L; Diogo J; Ferreira R; Silva D; Chaves C; Pássaro L; Paixão L; Cantón R;
    Int J Antimicrob Agents; 2020 Mar; 55(3):105887. PubMed ID: 31926283
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antimicrobial susceptibility of Gram-negative ESKAPE pathogens isolated from hospitalized patients with intra-abdominal and urinary tract infections in Asia-Pacific countries: SMART 2013-2015.
    Karlowsky JA; Hoban DJ; Hackel MA; Lob SH; Sahm DF
    J Med Microbiol; 2017 Jan; 66(1):61-69. PubMed ID: 28051952
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacodynamics of Ceftolozane plus Tazobactam Studied in an In Vitro Pharmacokinetic Model of Infection.
    MacGowan AP; Noel AR; Tomaselli SG; Nicholls D; Bowker KE
    Antimicrob Agents Chemother; 2016 Jan; 60(1):515-21. PubMed ID: 26552975
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combinatorial Pharmacodynamics of Ceftolozane-Tazobactam against Genotypically Defined β-Lactamase-Producing Escherichia coli: Insights into the Pharmacokinetics/Pharmacodynamics of β-Lactam-β-Lactamase Inhibitor Combinations.
    Soon RL; Lenhard JR; Bulman ZP; Holden PN; Kelchlin P; Steenbergen JN; Friedrich LV; Forrest A; Tsuji BT
    Antimicrob Agents Chemother; 2016 Apr; 60(4):1967-73. PubMed ID: 26729494
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy, pharmacokinetic and pharmacodynamic profile of ceftolozane + tazobactam in the treatment of complicated urinary tract infections.
    Wagenlehner FM; Alidjanov JF
    Expert Opin Drug Metab Toxicol; 2016 Aug; 12(8):959-66. PubMed ID: 27327964
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Activity of ceftolozane-tazobactam and comparators when tested against Gram-negative isolates collected from paediatric patients in the USA and Europe between 2012 and 2016 as part of a global surveillance programme.
    Shortridge D; Duncan LR; Pfaller MA; Flamm RK
    Int J Antimicrob Agents; 2019 May; 53(5):637-643. PubMed ID: 30716448
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antimicrobial activity of ceftolozane-tazobactam tested against gram-negative contemporary (2015-2017) isolates from hospitalized patients with pneumonia in US medical centers.
    Carvalhaes CG; Castanheira M; Sader HS; Flamm RK; Shortridge D
    Diagn Microbiol Infect Dis; 2019 May; 94(1):93-102. PubMed ID: 30642717
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Successful treatment of multidrug-resistant Pseudomonas aeruginosa breakthrough bacteremia with ceftolozane/tazobactam.
    Hernández-Tejedor A; Merino-Vega CD; Martín-Vivas A; Ruiz de Luna-González R; Delgado-Iribarren A; Gabán-Díez Á; Temprano-Gómez I; de la Calle-Pedrosa N; González-Jiménez AI; Algora-Weber A
    Infection; 2017 Feb; 45(1):115-117. PubMed ID: 27670678
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antimicrobial susceptibility profiles of gram-negative bacteria causing infections collected across India during 2014-2016: Study for monitoring antimicrobial resistance trend report.
    Veeraraghavan B; Jesudason MR; Prakasah JAJ; Anandan S; Sahni RD; Pragasam AK; Bakthavatchalam YD; Selvakumar RJ; Dhole TN; Rodrigues C; Roy I; Joshi S; Chaudhuri BN; Chitnis DS
    Indian J Med Microbiol; 2018; 36(1):32-36. PubMed ID: 29735823
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy of ceftolozane/tazobactam versus levofloxacin in the treatment of complicated urinary tract infections (cUTIs) caused by levofloxacin-resistant pathogens: results from the ASPECT-cUTI trial.
    Huntington JA; Sakoulas G; Umeh O; Cloutier DJ; Steenbergen JN; Bliss C; Goldstein EJ
    J Antimicrob Chemother; 2016 Jul; 71(7):2014-21. PubMed ID: 26994090
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Focus on ceftazidime-avibactam for optimizing outcomes in complicated intra-abdominal and urinary tract infections.
    Nicolau DP
    Expert Opin Investig Drugs; 2015; 24(9):1261-73. PubMed ID: 26145447
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Successful treatment of three severe MDR or XDR Pseudomonas aeruginosa infections with ceftolozane/tazobactam.
    Xipell M; Bodro M; Marco F; Martínez JA; Soriano A
    Future Microbiol; 2017 Nov; 12():1323-1326. PubMed ID: 28980834
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.